With a history of more than 70 years, and headquartered in Mougins, France, EA Pharma is a European leading pharmaceutical laboratory specialized in natural and efficient health nutrition products. The Company covers the three main areas (health, sport and cosmetics) through a diversified portfolio benefiting from positive underlying market trends in Europe. Pharmacies are the historical and prevailing distribution channel, notwithstanding the fact that EA Pharma has recently diversified its distribution network with e-commerce and exports now spanning four different continents. Over the past few years, the Company realized five strategic acquisitions under Motion Equity Partners ownership and intends to accelerate its external growth strategy to consolidate the European market.

“LGT Private Debt is pleased to support Motion Equity Partners as well as EA Pharma’s management team in their next development phase. We are particularly attracted by the positioning of the Company in its market, which has proven resilient even in the context of the Covid-19 crisis, as well as by its reknown pharmaceutical expertise and undisputed leadership in oligotherapy, which have enabled EA Pharma to successfully develop in complementary and promising adjacent markets," stated Kevin Abrial, a Partner at LGT Private Debt. "We have successfully partnered with Motion Equity Partners on previous transactions (including Altair, HolwegWeber, Résilians and Minlay) and value their hands-on investment strategy as well as their proven experience in transformational and growth projects.”

“LGT Private Debt has demonstrated its ability to react swiftly in understanding the strong potential of the Company and in providing a flexible and tailor-made financing solution,” said Anthony Baudoin, Partner at Motion Equity Partners. “We are pleased to team up again with LGT Private Debt as we believe they will be a valuable financing partner to support EA Pharma and its future development”.